ARTICLE | Clinical News
Valentis completes IL-2 Phase II enrollment
February 15, 2001 8:00 AM UTC
VLTS completed enrollment of 85 patients in a Phase IIb trial in Europe and Russia testing its IL-2 gene therapy in combination with chemotherapy to treat recurrent or refractory squamous cell carcino...